Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib for Maintenance Therapy After HSCT in Pediatric Patients With Acute Leukemia
NCT07498465Phase 1Withdrawn
- Sponsor
- Children's Oncology Group
- Start
- Sep 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of revumenib in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and mixed phenotype acute leukemia (MPAL), sponsored by Children's Oncology Group. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 4 more. Planned start Sep 2026; status: withdrawn.
02
Drugs
revumenib
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT07498465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498465.